BLISS-LN III期研究:狼疮肾炎中生物标志物与贝利尤单抗肾脏应答的关联
BLISS-LN III期研究纳入446例活动性狼疮肾炎成人患者,随机接受贝利尤单抗10 mg/kg或安慰剂联合标准治疗。事后分析显示,贝利尤单抗组IgA、IgM、抗dsDNA抗体及浆母细胞降幅更大,C3、C4升幅更大;基线IgA、抗C1q抗体、初始B细胞高及浆母细胞低、早期IgA/IgM/尿蛋白肌酐比下降与肾脏应答相关。
要点
- 贝利尤单抗较安慰剂更大幅度降低IgA、IgM、抗dsDNA抗体和浆母细胞,升高C3、C4。
- 基线高IgA、高抗C1q抗体、高初始B细胞及低浆母细胞预测贝利尤单抗肾脏应答。
- 早期IgA、IgM及尿蛋白肌酐比下降与贝利尤单抗肾脏应答相关。
核心结论
- 贝利尤单抗在不同诱导治疗组中对生物标志物的影响相似,并识别出与肾脏应答相关的基线和早期变化标志物。
研究设计与样本
- BLISS-LN为III期研究(NCT01639339),446例活动性狼疮肾炎成人随机接受贝利尤单抗10 mg/kg或安慰剂联合标准治疗。
- 标准治疗包括环磷酰胺或吗替麦考酚酯诱导,随后硫唑嘌呤或吗替麦考酚酯维持。
- 事后逻辑回归模型评估基线生物标志物水平及早期变化与第104周肾脏应答的关联。
主要发现
- 第104周,贝利尤单抗组较安慰剂组IgA、IgM、抗dsDNA抗体和浆母细胞百分比降幅数值更大,C3和C4升幅更大。
- 贝利尤单抗总体降低总CD19+ B细胞和初始B细胞,结果在总体人群和各诱导组中基本一致。
- 贝利尤单抗治疗患者的肾脏应答预测因素包括基线高IgA、高抗C1q抗体、高初始B细胞、低浆母细胞及早期IgA、IgM和尿蛋白肌酐比下降。
关键数值与推荐
- 贝利尤单抗剂量为静脉10 mg/kg,安慰剂对照。
- 446例患者中贝利尤单抗组环磷酰胺59例、吗替麦考酚酯164例;安慰剂组环磷酰胺59例、吗替麦考酚酯164例。
- 约50-60%患者有第104周治疗数据。
临床怎么用
- 基线IgA、抗C1q抗体、初始B细胞、浆母细胞及早期IgA、IgM、尿蛋白肌酐比变化可能辅助预测贝利尤单抗肾脏应答。
- 贝利尤单抗对生物标志物的影响在不同诱导治疗组中相似,支持其联合环磷酰胺或吗替麦考酚酯使用。
局限性
- 事后分析,约50-60%患者有第104周治疗数据。
- 未报告统计学显著性检验结果,部分结果为数值描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This study evaluated the effects of belimumab versus placebo on biomarker responses and identified predictive biomarkers for kidney response to belimumab in patients with lupus nephritis (LN) receiving different standard therapies. METHODS: BLISS-LN was a Phase 3 study (NCT01639339) of adults with active LN randomized to intravenous belimumab 10 mg/kg or placebo plus standard therapy (cyclophosphamide [CYC] or mycophenolate mofetil [MMF] as initial therapy followed by azathioprine or MMF). Absolute and percentage changes from baseline in immunoglobulins, anti-dsDNA and anti-C1q antibodies, C3 and C4, CD19+ B cells and subsets were assessed through Week 104. Post hoc logistic regression models assessed the association of baseline biomarker levels, and of early changes in biomarkers, with kidney response to belimumab in the overall population at Week 104. RESULTS: Of 446 patients (belimumab: 59 received CYC, 164 received MMF; placebo: 59 received CYC, 164 received MMF), approximately 50-60% had data on treatment at Week 104. At Week 104, numerically greater percentage reductions in IgA, IgM and anti-dsDNA antibodies and plasmablasts, and greater increases in C3 and C4 levels, were observed with belimumab versus placebo. Overall, belimumab reduced total CD19+ B cells and naïve B cells versus placebo. These results were generally consistent in the overall population and within each induction group. Predictors of kidney response observed in belimumab-treated patients included high baseline levels of IgA, anti-C1q antibodies and naïve B cells, low baseline plasmablasts and early decreases from baseline in levels of IgA, IgM and urinary protein to creatinine ratio. CONCLUSIONS: Similar effects of belimumab on biomarker outcomes were observed within the induction groups. Baseline biomarkers and early changes in biomarkers associated with kidney response to belimumab in LN were identified.
引用
- Rovin BH, Furie R, Malvar A, et al. Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritis. Kidney Int. 2026. PMID: 42055319. doi:10.1016/j.kint.2026.03.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。